INTRODUCTION AND OBJECTIVES: Adrenocortical carcinoma (ACC) is a relatively rare malignancy. We sought describe the trends in treatment approaches and outcome using national cancer database (NCDB).
METHODS: We reviewed the NCDB for patients diagnosed and treated for ACC between 2004 and 2013. Patients with metastatic disease at diagnosis were excluded from the analysis. All relevant demographic and oncological variables were analyzed. Chi square test compared categorical variables. ANOVA was used to compare mean in continuous variables. Kaplan Meier survival analysis was used to describe the overall survival. Log rank test compared the survival difference. Cox regression analysis was used to identify overall survival predictors.
RESULTS: 2214 patients were included in the study. The mean age was 54 years. The mean length of survival was 32.8 months. 1760 patients underwent surgery for ACC. Surgery was performed by open approach in 73% of patients, 21% had laparoscopic approach, and 6 % underwent robotic adrenalectomy, with proportions of open and MIS surgery being stable over the study period (p[0.327) CONCLUSIONS: Open adrenalectomy remains the most commonly utilized approach for management of localized ACC without significant change in overall utilization, and introduction of robotic technology has not had significant impact on proportion of minimally invasive procedures. Nonetheless, surgical approach did not significantly impact OS. For appropriately selected ACC, minimally invasive approaches may provide comparable outcomes. (FSCN1, FOXM1) , immune checkpoints (CD276) and innate immunity (CD161), were evaluated. Their correlation with clinical parameters and prognosis were analyzed using One-way ANOVA method, KaplaneMeier method and log-rank test. Univariate and multivariate Cox regression analyses were performed to identify the independent risk factor of ACC prognosis.
RESULTS: In TCGA data cohort, both the expression level of the emerging immune checkpoint, CD276, and the innate immune marker, KLRB1(CD161) were correlated with overall survival (OS, HR[2.4, P [ 0.033 and HR [ 0.41, P [ 0.03, respectively) and disease-free survival (DFS, HR[3.7, P [ 0.00049 and HR [ 0.32, P [ 0.0017, respectively) of ACC patients. They were also validated to be the independent influence factors of DFS in the multivariate analysis of validation cohort (n [ 47, HR[ 11.79, P < 0.05 and HR [ 0.22, P < 0.05, respectively) . More importantly, when combined the expression score of CD276 and CD161, a novel assessment model evaluating the tumor microenvironment was established and successfully classified the ACC patients into 4 subtypes with different risk of disease recurrence (P < 0.05). As the core molecules in the ACC microenvironment, CD276 and CD161 were also remarkably co-expressed with EMT-related FSCN1 and FOXM1, which were associated with poor prognosis of ACC (P < 0.05). The results further revealed a close association between immune status and EMT signature in the ACC microenvironment.
CONCLUSIONS: The expression of CD276 and CD161 correlate with tumor microenvironment status and prognosis of ACC patients. This microenvironment-based model further provides a promising risk assessment approach in ACC.
